Key Learning Community

JPMorgan Chase Announces $70 Million in New Commitments to Create Economic Opportunity Across France

Retrieved on: 
Wednesday, November 8, 2023
Government, Creation, JPMorgan Chase, Key Learning Community, Research, Energy transition, Paralympic Games, COVID-19, Les Compagnons de la chanson, Education, Corporate responsibility, Olympic Games, Mentorship, Project Spark, Organization, Grand Paris Express, Growth, Public sector, COVID, Employment, Paris, Business, Poverty, Partnership, Community, Woman, Investment, Renewable energy, Tutoring, Bank, Cryptocurrency, Management, Construction, Greater Paris

PARIS, Nov. 8, 2023 /PRNewswire/ -- As JPMorgan Chase continues to grow its business in France and learn from its recent philanthropic investments supporting underserved communities in Greater Paris, today the firm announced $70 million in new business and philanthropic commitments to connect individuals and entrepreneurs to economic opportunities across the country. This brings the firm's total commitment since 2018 to $100 million.

Key Points: 
  • The commitment will seek to align with France 2030, the country's national investment plan to create new and competitive pathways for economic growth in key sectors such as green and technology.
  • JPMorgan Chase will commit $50 million to this initiative and Bpifrance will commit €10 million to the initiative.
  • "I was present at Les Compagnons du Devoir in 2018 when Jamie Dimon announced JPMorgan Chase's $30 million commitment to Greater Paris.
  • Over the past five years, JPMorgan Chase has worked with the French government and non-profit leaders in Greater Paris to support programs and initiatives that create a more inclusive economy.

Healthcare Triangle Launches Ransomware Initiative Aimed at Protection and Prevention for Healthcare Providers

Retrieved on: 
Wednesday, July 12, 2023
CalPERS, Most, Senate, Health care, HCTI, Key Learning Community, Second Continental Congress, Hygiene, Congress, Hospital, Johns Hopkins University, Risk, Machine learning, Artificial intelligence, Federation, Health, Nursing, Risk management, CalSTRS

Both incidents have been attributed to a Russian hacker group known as the Cl0p ransomware syndicate.

Key Points: 
  • Both incidents have been attributed to a Russian hacker group known as the Cl0p ransomware syndicate.
  • Meanwhile, while large institutions and healthcare systems address major attacks, rural hospitals particularly vulnerable to risk are facing significant budget constraints for ransomware protection and need assistance from the federal government.
  • Healthcare Triangle applauds this and other actions by the U.S. Congress to address the growing threat of ransomware attacks, including the work of the Joint Ransomware Task Force (JRTF) , an interagency effort to reduce ransomware.
  • Healthcare Triangle’s ransomware prevention practices and training services include:

Bonterra Propels the Power of Community at Social Impact Leadership Conference

Retrieved on: 
Tuesday, June 28, 2022
Efficiency, Industry, Corporate social responsibility, Key Learning Community, Social Solutions, SILC, Technology, EveryAction, General manager, Fortune, Solution, National Angel Capital Organization, Family, Lovebox, Creativity, Program, Income, Conference, Tourism, Risk management

AUSTIN, Texas, June 28, 2022 /PRNewswire/ -- Following the Social Impact Leadership Conference (SILC), hosted by CyberGrants®, a Bonterra™ company, Bonterra today shares highlights and key successes from the event that will help drive the social good community. Back in-person for the first time since 2019, SILC brought together a wide range of Bonterra employees, customers, and partners to build meaningful connections, join thought-provoking panel discussions and sessions, and share social impact achievements through the Social Impact Awards ceremony.

Key Points: 
  • Social good software company celebrates community, Social Impact Awards, and meaningful service project during three-day, on-site event
    AUSTIN, Texas, June 28, 2022 /PRNewswire/ -- Following the Social Impact Leadership Conference (SILC) , hosted by CyberGrants, a Bonterracompany, Bonterra today shares highlights and key successes from the event that will help drive the social good community.
  • "At SILC we certainly achieved the conference theme of 'Connected Impact', making new connections and reestablishing previous ones," said Pete Karns, General Manager, Corporate Social Responsibility at Bonterra.
  • "The power of presence, and of our community, could be felt and we had a unique opportunity to recognize that, from our engaging sessions to our Social Impact Awards to our group service project.
  • While on-site in Austin, Bonterra had the opportunity to recognize several customers and partners, sharing their social impact achievements as part of the Social Impact Awards.

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

Retrieved on: 
Wednesday, October 27, 2021
Safety, B-cell lymphoma, Disease, U.S. Securities and Exchange Commission, International, Clinical trial, Webcast, COVID-19, Lymphoid leukemia, Therapy, MTD, GLOBE, Enzyme, Research, PD, BTK, Survival, Security (finance), Private Securities Litigation Reform Act, ID, Lymphoma, Lymphatic system, Annual report, Company, Male, CLL, Clinic, DLBCL, Immunomodulatory imide drug, Goal, Index (publishing), TPD, Cohort, SLL, SEC, Immunotherapy, PK, Mantle cell lymphoma, Protein, MCL, Nasdaq, Cancer, Mutation, Patient, Investor, Factor X, Key Learning Community, Macroglobulinemia, Telephone, Adult, Forward-looking statement, Intention, Lymphocytosis, Pharmacokinetics, Chronic lymphocytic leukemia, Follicular lymphoma, Infrared spectroscopy correlation table, ClinicalTrials.gov, Fine chemical, Pharmaceutical industry

SAN FRANCISCO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced initial data demonstrating clinically meaningful degradation of Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory B cell malignancies, including in a chronic lymphocytic leukemia (CLL) patient with significant mutations in the BTK gene associated with resistance to standard of care BTK inhibitors. These results will be presented by Nurix’s president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurix’s senior vice president of clinical development Robert J. Brown, M.D., at the 4th Annual Targeted Protein Degradation (TPD) Summit at 11:45 a.m. ET today, October 27, 2021. The slides for this presentation will be made available in the investor section of the company’s website.

Key Points: 
  • The initial data from our study are the first proof-of-mechanism of targeted protein degradation in patients with hematologic malignancies, said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix.
  • BTK degradation exceeded 80% at steady state in the first dose cohort and exceeded 90% in the second dose cohort.
  • The Phase 1a dose escalation portion of the Phase 1a/1b trial is ongoing with enrollment of patients with a variety of relapsed or refractory B cell malignancies.
  • The multicenter Phase 1a/1b study is designed to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of orally administered NX-2127 in adult patients with relapsed or refractory B-cell malignancies.

Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit

Retrieved on: 
Thursday, October 21, 2021
Research, SAN, Cancer, Goal, TPD, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Key Learning Community, SEC, Next wave, Oncology, Annual report, Forward-looking statement, Protein, Intention, COVID-19, Nasdaq, Therapy, GLOBE, Enzyme, Fine chemical

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurixs president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurixs chief scientific officer Gwenn M. Hansen, Ph.D., will participate in several sessions of the 4th Annual Targeted Protein Degradation (TPD) Summit, which will be held virtually October 26-29, 2021.

Key Points: 
  • SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurixs president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurixs chief scientific officer Gwenn M. Hansen, Ph.D., will participate in several sessions of the 4th Annual Targeted Protein Degradation (TPD) Summit, which will be held virtually October 26-29, 2021.
  • Nurixs drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
  • Nurixs wholly owned pipeline includes targeted protein degraders of Brutons tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation.
  • Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct.

Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting

Retrieved on: 
Saturday, October 9, 2021
IOP, Private Securities Litigation Reform Act, Inflammation, DME, Plasma protein binding, History, Technology, Adverse effect, Fast Track, AMD, Food, Diabetic retinopathy, GLOBE, Time, Safety, Adverum Biotechnologies, Publication, SEC, Linear code, Society, Diabetes, Patient safety, Review, ASRS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pathology, Degenerative disease, IVT, Eye, Intraocular pressure, Clinical trial, Patient, Disease, Research, Steroid, Nasdaq, Key Learning Community, SUSAR, Pharmaceutical industry, Cryptocurrency

Adverum is planning clinical development of ADVM-022 at low doses (2 x 10^11 vg/eye and lower) in patients with wet age-related macular degeneration (wet AMD).

Key Points: 
  • Adverum is planning clinical development of ADVM-022 at low doses (2 x 10^11 vg/eye and lower) in patients with wet age-related macular degeneration (wet AMD).
  • Last weekend, new long-term data from the OPTIC trial of ADVM-022 for wet AMD were presented at the Retina Societys 54th Annual Scientific Meeting on October 1, 2021.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Retail Experts Affirm Brick and Mortar is Here to Stay

Retrieved on: 
Wednesday, August 4, 2021
Marketing, Merchandising, Business, Brick and mortar, Costs, Customer service, Sales, Online shopping, Retail

"The COVID-19 pandemic forced retailers to quickly shift their operations to online and multi-channel options in order to survive. Yet one thing retail leaders can agree on -- especially with more of the population getting vaccinated and businesses resuming operations -- the brick and mortar store is not going anywhere," said Pranav Tyagi, Tango's President and CEO who gave the summit's keynote address on The Future of Brick and Mortar Retail. "Retail strategies may be changing to accommodate greater omnichannel experiences, but it is clear that the physical store is the foundation of a successful retailer and technology will continue to play a huge role in bringing the two together to create a seamless consumer experience."

Key Points: 
  • "The COVID-19 pandemic forced retailers to quickly shift their operations to online and multi-channel options in order to survive.
  • Yet one thing retail leaders can agree on -- especially with more of the population getting vaccinated and businesses resuming operations -- the brick and mortar store is not going anywhere," said Pranav Tyagi, Tango's President and CEO who gave the summit's keynote address on The Future of Brick and Mortar Retail.
  • Balancing friction in the brick and mortar retail experience:
    Consumers have always valued speed and efficiency, but there are now additional values that became more apparent for shoppers during the pandemic, such as convenience and cleanliness.
  • This could mean retraining associates, shifting employees into new roles, or even establishing new positions focused on alternate delivery methods.